RxDoctor Payments Data

John Manubay, MD

Family Medicine · York, PANPI 1467538942

Payments from drug & device makers

$10,848in general payments, 2019–2025

Across 609 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$985
  • Lilly USA, LLC$671
  • GSK$661
  • Pfizer$656
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$10,61298%
  • Education$2362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,848 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$94,678
Medicare patients
275
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$74,844
EliquisApixaban53$57,089
OzempicSemaglutide47$50,430
JanuviaSitagliptin Phosphate34$38,463
XareltoRivaroxaban41$27,218
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$19,052
FarxigaDapagliflozin Propanediol22$16,856
Breo ElliptaFluticasone/Vilanterol26$15,169
LinzessLinaclotide23$14,701
TradjentaLinagliptin16$9,055
Tresiba Flextouch U-100Insulin Degludec20$8,865
JentaduetoLinagliptin/Metformin Hcl11$5,813
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,440
Lantus SolostarInsulin Glargine,hum.Rec.Anlog48$5,095
Novolog FlexpenInsulin Aspart29$4,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$560$89,71383 claims
PfizerEliquis$656$57,08953 claims
Novo NordiskOzempic$1,421$50,43047 claims
MerckJanuvia$97$38,46334 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,546$35,90751 claims
Johnson & JohnsonXarelto$26$27,21841 claims
GSKBreo Ellipta$661$15,16926 claims
AbbVieLinzess$985$14,70123 claims
Sanofi-aventis U.S. LLCLantus$568$2,55223 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$45$2,283203 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in York

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →